Cargando…

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma

Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Franses, Joseph W, Lim, Mir, Burgoyne, Adam M, Mody, Kabir, Lennerz, Jochen, Chang, Jeremy, Imperial, Robin, Dybel, Stacey N, Dinh, Thi M, Masannat, Jude, Weipert, Caroline M, Hsiehchen, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632309/
https://www.ncbi.nlm.nih.gov/pubmed/36103364
http://dx.doi.org/10.1093/oncolo/oyac189
_version_ 1784824006645383168
author Franses, Joseph W
Lim, Mir
Burgoyne, Adam M
Mody, Kabir
Lennerz, Jochen
Chang, Jeremy
Imperial, Robin
Dybel, Stacey N
Dinh, Thi M
Masannat, Jude
Weipert, Caroline M
Hsiehchen, David
author_facet Franses, Joseph W
Lim, Mir
Burgoyne, Adam M
Mody, Kabir
Lennerz, Jochen
Chang, Jeremy
Imperial, Robin
Dybel, Stacey N
Dinh, Thi M
Masannat, Jude
Weipert, Caroline M
Hsiehchen, David
author_sort Franses, Joseph W
collection PubMed
description Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.
format Online
Article
Text
id pubmed-9632309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96323092022-11-04 Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma Franses, Joseph W Lim, Mir Burgoyne, Adam M Mody, Kabir Lennerz, Jochen Chang, Jeremy Imperial, Robin Dybel, Stacey N Dinh, Thi M Masannat, Jude Weipert, Caroline M Hsiehchen, David Oncologist Brief Communication Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC. Oxford University Press 2022-09-14 /pmc/articles/PMC9632309/ /pubmed/36103364 http://dx.doi.org/10.1093/oncolo/oyac189 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Franses, Joseph W
Lim, Mir
Burgoyne, Adam M
Mody, Kabir
Lennerz, Jochen
Chang, Jeremy
Imperial, Robin
Dybel, Stacey N
Dinh, Thi M
Masannat, Jude
Weipert, Caroline M
Hsiehchen, David
Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
title Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
title_full Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
title_fullStr Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
title_full_unstemmed Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
title_short Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
title_sort profile and predictors of blood tumor mutational burden in advanced hepatocellular carcinoma
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632309/
https://www.ncbi.nlm.nih.gov/pubmed/36103364
http://dx.doi.org/10.1093/oncolo/oyac189
work_keys_str_mv AT fransesjosephw profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT limmir profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT burgoyneadamm profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT modykabir profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT lennerzjochen profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT changjeremy profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT imperialrobin profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT dybelstaceyn profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT dinhthim profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT masannatjude profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT weipertcarolinem profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma
AT hsiehchendavid profileandpredictorsofbloodtumormutationalburdeninadvancedhepatocellularcarcinoma